Browse the evidence

In real-world commercial insurance populations without diabetes, one-year persistence on GLP-1 receptor agonists for obesity treatment is low (32.3%), with significant variation by product, contradicting high persistence rates reported in clinical trials.

If you are using a GLP-1 medication for weight loss, expect that staying on it for a full year is challenging. Real-world data shows only about 1 in 3 people stay on therapy for a year, and this varies by drug. Weekly injections (like semaglutide) tend to have better persistence than daily ones (like liraglutide). Discuss any side effects or supply issues with your doctor immediately rather than stopping abruptly, as discontinuation often leads to weight regain.

Pharmacological activation of brown and beige adipose tissue thermogenesis via beta-3 adrenergic signaling or UCP1-independent futile cycles increases energy expenditure and improves systemic metabolic health.

Your fat tissue is not just storage; it actively regulates your metabolism. While cold exposure can activate brown fat, current medical strategies focus on pharmacological agents (like GLP-1 agonists) that may indirectly support metabolic health. Understanding that visceral fat is metabolically harmful while subcutaneous fat is more neutral can guide lifestyle choices, but surgical removal of fat is not a cure for metabolic disease.

Premenopausal women exhibit sex-specific fat distribution characterized by preferential subcutaneous adipose tissue (SAT) storage and higher brown adipose tissue (BAT) activity, which provides metabolic protection against visceral obesity and cardiovascular disease compared to men.

If you are a premenopausal woman, your body naturally stores fat in your hips and thighs (subcutaneous) rather than around your organs (visceral), and you likely have more active brown fat for energy burning. This is a biological advantage for metabolic health. Do not equate higher total body fat with higher health risk compared to men; your distribution pattern is protective.

Coronary Microvascular Dysfunction (CMD) is a significant predictor of adverse cardiovascular events, heart failure with preserved ejection fraction (HFpEF), and mortality in diabetic patients, even in the absence of obstructive coronary artery disease.

Normal results on a standard angiogram (looking for big blockages) do not guarantee heart health if you have diabetes. Microvascular dysfunction can still cause heart failure and heart attacks. Monitoring for symptoms like shortness of breath and chest pain is crucial, as these may signal microvascular issues.

GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.

Be aware that GLP-1 medications can slightly increase your risk of gallbladder issues, such as gallstones or inflammation. This risk is higher if you take higher doses or use the medication for a long time. While the absolute risk is low, report any severe abdominal pain to your doctor promptly.

Obesity alters the pharmacokinetics of drugs, affecting absorption, distribution, metabolism, and excretion, which may necessitate dose adjustments for certain medications.

If you have obesity, tell your doctor about all medications you take. Your body may process drugs differently, requiring dose adjustments for safety and effectiveness, especially for drugs metabolized by the liver or kidneys.

Obesity induces chronic low-grade inflammation (LGCI) via adipose tissue hypertrophy, immune cell infiltration (M1 macrophages), and cytokine release (TNF-α, IL-6, IL-1β), which disrupts insulin signaling through JNK and NF-κB pathways, leading to systemic insulin resistance and metabolic dysfunction.

If you have obesity, your body is likely in a state of chronic, low-grade inflammation that actively works against your metabolic health. This isn't just 'being fat'; it's a biological state that disrupts how your body handles insulin and energy. Addressing this inflammation through lifestyle changes (diet, exercise) or medical interventions is crucial for breaking the cycle of metabolic dysfunction.

Global Positioning Systems (GPS) and metabolic power calculations tend to underestimate energy expenditure during soccer match-play compared to indirect calorimetry, particularly during recovery phases.

Be cautious when using GPS devices to estimate calorie burn. They often underestimate energy expenditure, especially during rest periods in soccer. Use this data as a rough guide rather than an exact number when planning nutrition.

Tirzepatide slows the rate of eGFR decline in patients with type 2 diabetes, including those with preserved kidney function (eGFR >60 mL/min/1.73 m2) and normoalbuminuria.

Even if your kidney function tests are currently normal, tirzepatide can help protect your kidneys from future decline. Clinical data shows that this medication slows the rate of kidney function loss compared to insulin, regardless of whether you currently have signs of kidney disease. This makes it a valuable preventive tool for long-term kidney health in people with type 2 diabetes.

Oral branched-chain amino acid (BCAA) supplementation provides negligible benefits for athletic performance and body composition in trained athletes, regardless of supplementation duration or dosage.

If you are an athlete, stop spending money on BCAA supplements for performance or muscle gain. The evidence shows they provide negligible benefits over a normal diet. Ensure you are eating enough total protein daily instead. BCAAs might help slightly with muscle soreness after heavy resistance training, but this is not a guaranteed or significant benefit for most people.

In strength-trained individuals, acute carbohydrate intake does not improve resistance training performance (repetitions to failure or total volume) when compared to a fed state with a 2-5 hour post-prandial window, provided the workout volume is moderate (≤10 sets per muscle group).

If you eat a normal meal 2-5 hours before lifting, you do not need to force-feed yourself carbohydrates right before training to get better reps or strength. Your muscles have enough glycogen. Save the carbs for post-workout or general daily intake. If you train fasted or do extremely high volume (>10 sets/muscle), then carbs may help, but for standard sessions, don't stress about pre-workout carbs.

Long-term carbohydrate manipulation (weeks to months) does not influence strength gains or hypertrophy in strength-trained individuals, provided total caloric and protein intake are adequate.

You do not need to eat a high-carbohydrate diet to build muscle or get strong. Focus on hitting your protein targets and maintaining a caloric surplus (if bulking) or deficit (if cutting). You can choose your carbohydrate intake based on preference, activity level, or metabolic health without sacrificing strength gains.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) produce a statistically significant but clinically modest reduction in systolic blood pressure (SBP) compared to placebo, with effects ranging from -1.46 to -3.40 mmHg.

GLP-1 medications (like Ozempic or Wegovy) consistently lower systolic blood pressure by a small but measurable amount (1-3 mmHg). This benefit occurs regardless of whether you have diabetes. It is not a substitute for blood pressure medication, but it is a favorable side effect that supports heart health.

GLP-1 receptor agonists generally do not significantly reduce diastolic blood pressure (DBP), with the exception of exenatide.

Do not expect GLP-1 medications to significantly lower your diastolic (bottom number) blood pressure, unless you are taking exenatide. Most GLP-1s primarily affect systolic pressure.

Selective, long-acting NK2R agonists (e.g., EB1002) reduce body weight and improve insulin sensitivity in obese mice and diabetic macaques by simultaneously increasing energy expenditure and suppressing appetite without causing aversive side effects.

This research identifies a new drug target (NK2R) that could lead to medications for obesity and type 2 diabetes. These drugs work by making your body burn more energy and reducing your appetite, without causing the unpleasant side effects often associated with other weight loss treatments. While promising in animals, this is not yet a human treatment.

Epicardial adipose tissue volume is a stronger predictor of atrial fibrillation risk than general anthropometric indices like BMI or waist circumference.

Fat stored directly around the heart (epicardial fat) is a major driver of atrial fibrillation in obese people. This risk is higher than what BMI alone suggests. Weight loss reduces this fat and improves heart rhythm.

Bariatric surgery reduces all-cause and cardiovascular mortality and heart failure incidence, but its effect on reducing *incident* atrial fibrillation is not statistically significant.

Bariatric surgery significantly reduces death and heart failure in obese patients, but it does not significantly reduce the risk of *developing* new atrial fibrillation. It is still beneficial for overall heart health.

Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) is superior to behavioral and pharmacological interventions for long-term weight loss maintenance because it alters gut hormones and brain reward circuits, reducing compensatory hunger and metabolic adaptation.

Bariatric surgery is currently the most effective long-term intervention for obesity, largely because it biologically reduces hunger and alters food reward. However, it is not a permanent cure; significant weight regain can still occur. It should be viewed as a tool that facilitates weight loss, but long-term success still requires ongoing behavioral and nutritional support.

Obesity is a chronic, relapsing disease driven by a syndemic interaction of macro-systems (climate, globalization, policy) and micro-systems (behavior, environment), rather than solely individual choice.

Stop blaming yourself or others for obesity. Recognize it as a chronic disease shaped by your environment, food systems, and socioeconomic status. Seek medical help and policy changes rather than relying solely on willpower.

Body Mass Index (BMI) is an insufficient and potentially misleading sole diagnostic measure for obesity due to its inability to capture phenotypic heterogeneity and visceral adiposity.

Do not rely on BMI alone to assess your health. Ask your doctor for additional metrics like waist circumference, blood pressure, and blood sugar levels to get a complete picture of your metabolic health.

SGLT2 inhibitors and GLP-1 receptor agonists reduce major cardiovascular events and improve cardiac structure/function through anti-inflammatory, anti-oxidative, and metabolic mechanisms, independent of glucose lowering.

If you have T2DM and heart disease or risk factors, ask your doctor about SGLT2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they actively protect your heart, reduce inflammation, and lower the risk of heart failure and death, regardless of your glucose levels.

SGLT2 inhibitors reduce oxidative stress and inflammation in cardiac tissue by improving nitric oxide bioavailability, stimulating Nrf2/ARE signaling, and suppressing NADPH oxidase.

SGLT2 inhibitors help protect heart cells from damage caused by oxidative stress and inflammation, which contributes to their ability to prevent heart failure.

SGLT2 inhibitors reduce the incidence of atrial fibrillation (AF) and atrial flutter (AFL) by reducing atrial dilation, intracellular sodium/calcium levels, and epicardial adipose tissue.

Taking SGLT2 inhibitors may lower your risk of developing irregular heartbeats like atrial fibrillation, which is a common complication in diabetes and heart failure.

GLP-1 receptor agonists reduce stroke risk but do not significantly prevent the onset of atrial fibrillation or atrial flutter, and may increase heart rate.

GLP-1 RAs are effective at reducing stroke risk, but unlike SGLT2 inhibitors, they do not appear to prevent atrial fibrillation and may slightly increase heart rate.